{"nctId":"NCT04157686","briefTitle":"MT10109L in the Long-term, Open-label Treatment of Glabellar Lines (GL) and Lateral Canthal Lines (LCL)","startDateStruct":{"date":"2019-10-23","type":"ACTUAL"},"conditions":["Glabellar Lines","Lateral Canthal Lines"],"count":957,"armGroups":[{"label":"Placebo/MT10109L Dose 1","type":"EXPERIMENTAL","interventionNames":["Drug: MT10109L Dose 1"]},{"label":"Placebo/MT10109L Dose 2","type":"EXPERIMENTAL","interventionNames":["Drug: MT10109L Dose 2"]},{"label":"Placebo/MT10109L Dose 1 + Dose 2","type":"EXPERIMENTAL","interventionNames":["Drug: MT10109L Dose 1 + Dose 2"]},{"label":"MT10109L Dose 1/Dose 1","type":"EXPERIMENTAL","interventionNames":["Drug: MT10109L Dose 1"]},{"label":"MT10109L Dose 2/Dose 2","type":"EXPERIMENTAL","interventionNames":["Drug: MT10109L Dose 2"]},{"label":"MT10109L Dose 1/Dose 1+2","type":"EXPERIMENTAL","interventionNames":["Drug: MT10109L Dose 1 + Dose 2"]},{"label":"MT10109L Dose 2/Dose 1+2","type":"EXPERIMENTAL","interventionNames":["Drug: MT10109L Dose 1 + Dose 2"]},{"label":"MT10109L Dose 1+2/Dose 1+2","type":"EXPERIMENTAL","interventionNames":["Drug: MT10109L Dose 1 + Dose 2"]}],"interventions":[{"name":"MT10109L Dose 1","otherNames":[]},{"name":"MT10109L Dose 2","otherNames":[]},{"name":"MT10109L Dose 1 + Dose 2","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Completion of lead-in Phase 3 study;\n* Female participants must not be pregnant or planning to get pregnant and willing to minimize the risk of inducing pregnancy for the duration of the clinical study and follow-up period.\n\nExclusion Criteria:\n\n* Known immunization or hypersensitivity to any botulinum toxin serotype;\n* Any medical condition that may put the participant at increased risk with exposure to MT10109L including diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or any other condition that might interfere with neuromuscular function;\n* Known allergy or sensitivity to any of the components of the study interventions, or any materials used in the study procedures;\n* Females who are pregnant, nursing, or planning a pregnancy during the study;\n* Participants who plan for an extended absence away from the immediate area of the study site that would preclude them from returning for all protocol-specified study visits.","healthyVolunteers":false,"sex":"ALL","minimumAge":"19 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants Who Experienced Any Adverse Event (AE)","description":"The safety analyses were conducted in the Intent-to-Treat (ITT) population. All adverse events were collected from the signing of the ICF to 30 days after the participant's last study visit.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"39","spread":null},{"groupId":"OG002","value":"80","spread":null},{"groupId":"OG003","value":"89","spread":null},{"groupId":"OG004","value":"74","spread":null},{"groupId":"OG005","value":"80","spread":null},{"groupId":"OG006","value":"89","spread":null},{"groupId":"OG007","value":"183","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Who Experienced Treatment-Related Adverse Events (TEAEs)","description":"This section focuses primarily on Treatment-Related (Study drug or procedure) Adverse Events(TEAEs). TEAEs are AEs with onset date on or after first dose of study intervention (placebo or MT10109L) in the pivotal study and â‰¤ 30 days after the study exit visit in the extension study.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"31","spread":null},{"groupId":"OG003","value":"34","spread":null},{"groupId":"OG004","value":"11","spread":null},{"groupId":"OG005","value":"22","spread":null},{"groupId":"OG006","value":"42","spread":null},{"groupId":"OG007","value":"73","spread":null}]}]}]},{"type":"PRIMARY","title":"Mean Change From Baseline in Pulse Rate (Beats Per Minute)","description":"The outcome reported here is the mean change in pulse rate from baseline to study exit.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":"15.01"},{"groupId":"OG001","value":"-2.2","spread":"13.35"},{"groupId":"OG002","value":"-1.2","spread":"10.95"},{"groupId":"OG003","value":"2.0","spread":"12.77"},{"groupId":"OG004","value":"0.6","spread":"11.58"},{"groupId":"OG005","value":"0.7","spread":"10.97"},{"groupId":"OG006","value":"3.0","spread":"10.34"},{"groupId":"OG007","value":"1.0","spread":"8.93"}]}]}]},{"type":"PRIMARY","title":"Mean Change From Baseline in Systolic Blood Pressure (mm Hg)","description":"The outcome reported here is the mean change in Systolic BP from baseline to study exit.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"12.59"},{"groupId":"OG001","value":"-1.9","spread":"10.44"},{"groupId":"OG002","value":"1.9","spread":"14.44"},{"groupId":"OG003","value":"0.6","spread":"16.72"},{"groupId":"OG004","value":"1.1","spread":"13.84"},{"groupId":"OG005","value":"1.8","spread":"15.24"},{"groupId":"OG006","value":"1.4","spread":"14.17"},{"groupId":"OG007","value":"-0.4","spread":"13.83"}]}]}]},{"type":"PRIMARY","title":"Mean Change From Baseline in Diastolic Blood Pressure (mm Hg)","description":"The outcome reported here is the mean change in Diastolic BP from baseline to study exit.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":"11.3"},{"groupId":"OG001","value":"-0.6","spread":"11.75"},{"groupId":"OG002","value":"1.3","spread":"9.61"},{"groupId":"OG003","value":"1.5","spread":"11.68"},{"groupId":"OG004","value":"0.7","spread":"7.57"},{"groupId":"OG005","value":"0.0","spread":"10.62"},{"groupId":"OG006","value":"2.3","spread":"9.53"},{"groupId":"OG007","value":"-0.3","spread":"9.46"}]}]}]},{"type":"PRIMARY","title":"Mean Change From Baseline in Respiratory Rate (Breaths Per Minute)","description":"The outcome reported here is the mean change in respiratory rate from baseline to study exit.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"2.09"},{"groupId":"OG001","value":"0.6","spread":"2.15"},{"groupId":"OG002","value":"-0.5","spread":"1.92"},{"groupId":"OG003","value":"0.2","spread":"2.78"},{"groupId":"OG004","value":"0.5","spread":"1.94"},{"groupId":"OG005","value":"-0.4","spread":"2.29"},{"groupId":"OG006","value":"0.4","spread":"2.21"},{"groupId":"OG007","value":"-0.1","spread":"2.3"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Binding and Neutralizing Antibodies","description":"Only samples that tested positive in the binding antibody confirmatory assay were evaluated for neutralizing antibodies. The participants with positive neutralizing antibodies are only shown.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"2","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":55},"commonTop":["COVID-19","Nasopharyngitis","Headache","Injection site pain","Upper respiratory tract infection"]}}}